Patient: Page 2
-
Kevin Dietsch via Getty Images
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
By Amy Baxter • March 6, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Anna Moneymaker via Getty Images
After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections
Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.
By Amy Baxter • March 1, 2024 -
Permission granted by Gianluca Pirozzi
ProfileBehind a big-name rare disease biotech, an exec draws from personal experience
The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.
By Alexandra Pecci • Feb. 27, 2024 -
Permission granted by Iovance Biotherapeutics
Behind the breakthrough cancer therapy that just won a historic FDA nod
The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.
By Kelly Bilodeau • Feb. 21, 2024 -
Courtesy of Kite Pharma, Inc.
Kite’s next-gen CAR-T aims include quicker production and more disease targets
While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.
By Kelly Bilodeau • Feb. 20, 2024 -
stock via Getty Images
‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing
Researchers are unleashing the powers of AI for precision medicine, drug development and more.
By Alexandra Pecci • Feb. 15, 2024 -
Permission granted by Pfizer
‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
By Michael Gibney • Feb. 14, 2024 -
iStock via Getty Images
These 4 drugs had tons of promise — and they flopped. What happened?
No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.
By Alexandra Pecci • Feb. 13, 2024 -
Stock via Getty Images
Tonix closes in on the first new fibromyalgia drug in more than a decade
In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.
By Kelly Bilodeau • Jan. 29, 2024 -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024 -
Stock via Getty Images
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Dan Kitwood/Getty Images via Getty Images
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.
By Michael Gibney • Jan. 25, 2024 -
Stock via Getty Images
Breast cancer tops list of most studied diseases
The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.
By Kelly Bilodeau • Jan. 24, 2024 -
Stock via Getty Images
Controversial challenge trials offer unparalleled innovation — with ethical bumps
Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.
By Kelly Bilodeau • Jan. 22, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Getty Images via Getty Images
An enduring COVID mystery: Why some do fine and others die
The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.
By Alexandra Pecci • Jan. 17, 2024 -
Stock via Getty Images
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Stock via Getty Images
OpinionPharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
E+ via Getty Images
How J&J is tackling a ‘secondary pandemic’ in the Black community
J&J is leading a grassroots effort to improve mental health access and care.
By Alexandra Pecci • Jan. 8, 2024 -
Stock via Getty Images
Regulatory twists and turns are coming for biopharma in 2024
New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.
By Kelly Bilodeau • Jan. 8, 2024 -
iStock via Getty Images
Alzheimer’s research is hot, but successful patient recruitment will determine its future
Key strategies for bringing more patients into the clinical trial fold.
By Kelly Bilodeau • Jan. 4, 2024 -
Stock via Getty Images
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Massachusetts General Hospital
Deep DiveAs ALS research booms, one treatment center finds itself in the spotlight
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
By Jacob Bell • Dec. 22, 2023
Previous
